Search

Your search keyword '"Brian W. Dymock"' showing total 62 results

Search Constraints

Start Over You searched for: Author "Brian W. Dymock" Remove constraint Author: "Brian W. Dymock"
62 results on '"Brian W. Dymock"'

Search Results

1. Predicting Tacrolimus Concentrations in the Skin of Adult Kidney Transplant Recipients: A Feasibility Study

2. Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality

3. Intracellular Hyper-Acidification Potentiated by Hydrogen Sulfide Mediates Invasive and Therapy Resistant Cancer Cell Death

4. Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome

5. Intranasal administration of a stapled relaxin‐3 mimetic has anxiolytic‐ and antidepressant‐like activity in rats

6. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat

7. Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)

8. Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90)

9. Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality

10. Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat

11. Analysis of Protein Target Interactions of Synthetic Mixtures by Affinity-LC/MS

12. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor

13. Recently discovered EZH2 and EHMT2 (G9a) inhibitors

14. Antioxidants inhibit neuronal toxicity in Parkinson's disease‐linked LRRK2

15. Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131)

16. SAHA and cisplatin sensitize gastric cancer cells to doxorubicin by induction of DNA damage, apoptosis and perturbation of AMPK-mTOR signalling

17. Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome

18. Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome

19. Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

20. Discovery of medium ring thiophosphorus based heterocycles as antiproliferative agents

21. Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents

22. A novel slow-releasing hydrogen sulfide donor, FW1256, exerts anti-inflammatory effects in mouse macrophages and in vivo

23. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)

24. A Small Molecule Targeting the Transmembrane Domain of Death Receptor p75NTR Induces Melanoma Cell Death and Reduces Tumor Growth

25. Predicting chemotherapeutic drug combinations through gene network profiling

26. Overcoming Chloroquine Resistance in Malaria: Design, Synthesis, and Structure-Activity Relationships of Novel Hybrid Compounds

27. Mutation of histone H3 serine 86 disrupts GATA factor Ams2 expression and precise chromosome segregation in fission yeast

28. Fluorescent Probes for H2S Detection and Quantification

29. Discovery of New H2S Releasing Phosphordithioates and 2,3-Dihydro-2-phenyl-2-sulfanylenebenzo[d][1,3,2]oxazaphospholes with Improved Antiproliferative Activity

30. GYY4137, a novel water-soluble, H2S-releasing molecule

31. The rise of epigenetic drug discovery

32. Fluorescent Probes for H2S Detection and Quantification

33. Selective JAK inhibitors

34. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602

36. Antioxidant kinase inhibitors for LRRK2 Parkinson's disease

38. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012

40. Hydrogen sulfide is an endogenous regulator of aging in Caenorhabditis elegans

41. VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

42. Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis

43. Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)

46. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity

47. Hydrogen Sulfide Promotes Adipogenesis in 3T3L1 Cells

48. [Untitled]

49. P28 Identification of a novel slow-releasing hydrogen sulfide donor for cancer therapy

50. Abstract 3591: Discovery of SB1317: A novel small molecule macrocycle with a unique kinase inhibitory spectrum in phase 1 clinical trials for hematological malignancies

Catalog

Books, media, physical & digital resources